Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: Current status and future prospects

Kekkaku

Volumn 86, Issue 1, 2011, Pages 9-16

  Yew, Wing Wai ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Extensively drug resistance tuberculosis (XDR TB); Management; Multidrug resistant tuberculosis (MDR TB)

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79957862485     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010global report on surveillance and response. Geneva. Switzerland. 2010. WHO/HTM/TB/2010.3.
2. Lalloo UG. Naidoo R. Amharam A: Recent advances in the medical and surgical treatment of multi-drug resistant tuberculosis. Curr Opin Pulm Med. 2006; 12: I79-K5.
3. Yew WW: Directly observed therapy, short-course: the best way to prevent multidrug-resistant tuberculosis. Chemotherapy. 1999: 45 Suppl 2: 26-33.
4. Thiam S. Le Fevre AM. Hane F, et al.: Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA. 2007; 297: 380-6.
5. Moulding TS, Le HQ, Rikleen D, et al.: Preventing drug-resistant tuberculosis with a fixed dose combination of isoni-azid and rifampin. Int J Tuberc Lung Dis. 2004; 8: 743-8.
6. Tarn CM. Chan SL. Kam KM. et al.: Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis. 2002: 6: 3-10.
7. Benator D, Bhattacharya M. Bozeman L. et al.: Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet. 2002; 360: 528-34.
8. Rosenthal IM, Zhang M, Williams KN: Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med. 2007: 4: e344.
9. Weiner M. Bock N. Peloquin CA. et al.: Tuberculosis Trials Consortium. Pharmacokinetics of rifapentine at 600,900. and 1200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med. 2004; 169: 1191-7.
10. Yew WW. Leung CC: Management of multidrug-resistant tuberculosis: Update 2007. Respirology. 2008: 13: 21-46.
11. Ling DI. Zwerling AA, Pai M: GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a metaanalysis. Eur Respir J. 2008: 32: 1165-74.
12. Moore DA, Evans CA, Gilman R.H., et al.: Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006: 355: 1539-50.
13. Espinal MA. Kim SJ. Suarez PG. et al.: Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000; 283: 2537-45.
14. Becerra MC. Freeman J. Bayona J. et al.: Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2000: 4: 108-14.
15. Mak A. Thomas A. Del Granado M. et al.: Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med. 2008: 178: 306-12.
16. World Health Organization: Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva. Switzerland. 2006. WHO/HTM/TB/2006.361.
17. Orenstein EW. Basu S, Shah NS: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic-review and meta-analysis. Lancet Infect Dis. 2009; 9: 153-61.
18. Yew WW, Chan CK, Chau C.H., et al.: Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin- containing regimens. Chest. 2000; 117: 744-51.
19. Park IN, Hong SB, Oh Y.M., et al.: Impact of short-term exposure to fluoroquinolones on ofloxacin resistance in HIV-negative patients with tuberculosis. Int J Tuberc Lung Dis. 2007; 11: 319-24.
20. Caminero JA: Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis. 2008; 12: 869-77.
21. Devasia RA, Blackman A, Gebretsadik T., et al.: Fluoroquinolones resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009; 180: 365-70.
22. Migliori GB. Lange C. Centis R, et al.: Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008; 31: 1155-9.
23. Kim DH, Kim HJ. Park SK, et al.: Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008; 178: 1075-82.
24. Blower S. Supervie V: Predicting the future of XDR tuberculosis. Lancet Infect Dis. 2007; 7: 443.
25. World Health Organization: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis - Emergency Update 2008. Geneva. Switzerland, 2008. WHO/HTM/TB/2008. 402.
26. Diacon AH, Pym A, Grobusch M., et al.: The diarylquinoline TMC-207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360: 2397-405.
27. Matsumoto M, Hashizume H, Tomishige T., et al.: OPC-67683. a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006; 3: e466.
28. Nuermberger E. Tyagi S. Tasneen R. et al.: Powerful bactericidal and sterilizing activity of a regimen containing PA-824. moxifloxacin. and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008: 52: 1522-4.
29. Mitnick CD, Castro KG. Harrington M. et al.: Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007; 4: e282.
30. Chan ED. Laurel V, Strand MJ. et al.: Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004; 169: 11039.
31. Torun T, Tahaoglu K. Ozmen I. et al.: The role of surgery and fluoroquinolones in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2007: 11: 979-85.
32. Park SK, Kim JH, Kang H. et al.: Pulmonary resection combined with rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis. 2009; 13: 170-5.
33. Motus IY. Skorniakov SN. Sokolov VA. et al.: Reviving an old idea: can artificial pneumonthorax play a role in the modern management of tuberculosis? Int J Tuberc Lung Dis. 2006; 10: 571-7.
34. Churchyard GJ, Kaplan G, Fallows D., et al.: Advances in immunotherapy for tuberculosis treatment. Clin Chest Med. 2009: 30: 769-82.
35. Gutierrez MG, Master SS. Singh SB, et al.: Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell. 2004; 119: 753-66.
36. Dawson R. Condos R, Tse D. et al.: Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One. 2009: 4: e6984.
37. Johnson JL. Hadad DJ. Boon WH, et al.: Early and extended early bactericidal activity of levofioxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2006; 10: 605-12.
38. Yew WW. Chan CK. Leung CC. et al.: Comparative roles of levofioxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003; 124: 1476-81.
39. Dheda K, Shean K, Zumla A. et al.: Early Treatment Outcomes of Extensively Drug-Resistant Tuberculosis in South Africa are poor regardless of HIV status. Lancet. 2010. May 18 [Epub ahead of print].
40. Migliori GB. Eker B. Richardson MD, et al.: TBNET Study Group. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009; 34: 387-93.
41. Koh WJ, Kwon OJ. Gwak H, et al.: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother. 2009; 64: 388-91.
42. Huang TS, Liu YC, Sy C.L., et al.: In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years. Antimicrob Agents Chemother. 2008; 52: 2226-7.
43. Williams KN, Stover CK, Zhu T, et al.: Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother. 2009; 53: 1314-9.
44. Katiyar SK, Bihari S, Prakash S., et al.: A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008: 12: 139-45.
45. Kwon YS, Kim YH, Suh G.Y., et al.: Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008; 47: 496-502.
46. Jeon DS, Kim DH, Kang H.S., et al.: Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2009: 13: 594-600.